Sutro Signs an Option Agreement with BioNova to Develop and Commercialize STRO-001 for Hematologic Cancers in Greater China

 Sutro Signs an Option Agreement with BioNova to Develop and Commercialize STRO-001 for Hematologic Cancers in Greater China

Sutro Signs an Option Agreement with BioNova to Develop and Commercialize STRO-001 for Hematologic Cancers in Greater China

Shots:

  • Sutro to receive $4M as licensing option fee, ~$200M as an option exercise fee, development, regulatory & commercial milestones along with royalties based on sales of STRO-001 in Greater China. BioNova to get STRO-001 from Sutro under clinical & commercial supply agreements
  • BioNova gets the option to acquire exclusive rights for the development & commercialization of STRO-001 in Greater China & will lead clinical development, regulatory approval & commercialization of STRO-001 in multiple indications, including NHL, MM & leukemia in the licensed countries
  • Sutro will hold development & commercial rights of STRO-001 globally outside of Greater China, including the US

Click here to­ read full press release/ article | Ref: PR Newswire | Image: Linkedin

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post